




FIG. 1A




FIG. 1B




FIG. 2




FIG. 3





FIG. 4



There are 11 antibodies tested under each condition (i.e., 11 bars in each set of bars). The 11 bars under each condition from left to right represent respectively clones BAP063 10F10, BAP063.9-13-1-FLAG, BAP063.9-29-2-FLAG, BAP063.9-45-2-FLAG, BAP063.9-13-3-FLAG, BAP063-21-3-FLAG, BAP063.9-21-4-FLAG, BAP063.9-29-4-FLAG, BAP063.9-48-3-FLAG, BAP063.9-13-4-FLAG, non-specific mAb, no mAb.

FIG. 5




FIG. 6A




FIG. 6B




FIG. 7




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D




FIG. 8E




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D




FIG. 10E




FIG. 10F




FIG. 10G




FIG. 10H




FIG. 11




FIG. 12

Naked Ab




FIG. 13A

ADC




FIG. 13B




FIG. 14A




FIG. 14B

Lymphocytes




FIG. 15




FIG. 16A




FIG. 16B




FIG. 17A




FIG. 17B




FIG. 17C




FIG. 17D




FIG. 18

Caption for Fig. 18

- a, If ≥ 2 DLT, enroll up to 6 patients in associated 2Q3W cohort and enroll 3 additional patients in previous cohort in parallel, if not previously enrolled
 - b, If ≥ 2 DLT, enroll up to 6 patients in the intermediate cohort and enroll 3 additional patients in previous cohort in parallel, if not previously enrolled
 - c, If ≤ 1 DLT, enroll up to 6 patients in dose cohorts in parallel
- Cohort 7A opens if ≤ 1 DLT in both Cohort 6 & 6A; Similarly, Cohort 8A opens if ≤ 1 DLT in both Cohort 7 & 7A

Exemplary Dosing Schedules





FIG. 19



Subject	Cancer Type	Dose	Subject	Cancer Type	Dose
1	Liposarcoma	1.8 mg/kg D1, 8 Q3W	10	Undifferentiated Pleomorphic Sarcoma	1.8 mg/kg D1, 8 Q3W
2	Undifferentiated Pleomorphic Sarcoma	1.8 mg/kg D1, 8 Q3W	11	Osteosarcoma	1.8 mg/kg D1, 8 Q3W
3	Liposarcoma	2.4 mg/kg D1, Q3W	12	Liposarcoma	1.8 mg/kg D1, 8 Q3W
4	Liposarcoma	1.8 mg/kg D1, Q3W	13	Liposarcoma	1.8 mg/kg D1, 8 Q3W
5	Synovial Sarcoma	1.8 mg/kg D1, 8 Q3W	14	Liposarcoma	1.8 mg/kg D1, Q3W
6	Liposarcoma	1.8 mg/kg D1, 8 Q3W	15	Undifferentiated Pleomorphic Sarcoma	1.8 mg/kg D1, 8 Q3W
7	Osteosarcoma	1.8 mg/kg D1, 8 Q3W	16	Undifferentiated Pleomorphic Sarcoma	1.8 mg/kg D1, 8 Q3W
8	Liposarcoma	1.8 mg/kg D1, 8 Q3W	17	Epithelial Sarcoma	1.8 mg/kg D1, Q3W
9	Liposarcoma	1.8 mg/kg D1, 8 Q3W			

FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24